Omeros shares slide following European regulatory setback for Narsoplimab
Omeros Corporation (NASDAQ: OMER) shares fell 4% after the European Medicines Agency's CHMP maintained a negative opinion on its drug narsoplimab for treating TA-TMA, despite U.S. FDA approval. The decision followed a re-examination and expert review, contrasting with the drug's success in the U.S. Omeros plans to terminate its European compassionate-use program and continues clinical studies for other conditions.
How this was made
The 30-second read
Why it matters
The EMA rejection curtails European market entry, likely reducing total addressable market and pressuring the stock.
Market read
The news directly impacts Omeros' share price and may influence sentiment toward other rare‑disease biotech firms awaiting EMA decisions.
What to watch
Potential future data from ARDS studies could reopen European discussions, and compassionate‑use supply may sustain some revenue.
Background
Omeros recently received FDA approval for narsoplimab (YARTEMLEA) in the U.S., positioning it as the only approved therapy for TA‑TMA.
Ticker impact
EMA's CHMP maintained a negative opinion and rejected Omeros' drug narsoplimab, causing a 4% share decline.
likely pressure as investors price in the EMA rejection and reduced European upside
The negative EMA decision is a fresh, material regulatory denial for a small‑cap biotech, directly affecting revenue prospects.
Market effects
Biotech/rare‑disease sector may see heightened scrutiny of EMA pathways.
European biotech stocks could experience modest pullback.
Limited to Omeros and peers; no broad market effect.
Counterpoint
The U.S. FDA approval and lack of REMS may still drive strong U.S. sales, offsetting the EU loss.
Key entities
- RegulatorEuropean Medicines Agency (EMA)
Issued the negative CHMP opinion on narsoplimab.
- CompanyOmeros Corporation
Developer of narsoplimab, facing European regulatory setback.
